June 28, 2022 at 7:27 pm
Kezar Life Sciences (KZR) Shoots Up 43% On Promising Study Data
Kezar Life Sciences (KZR) soared 43% today as it has announced promising top-line data from their phase II study, called MISSION, evaluating its lead pipeline candidate in patients with active lupus nephritis (LN). LN is a type of kidney diseased caused by the autoimmune disease systemic lupus erythematosus (SLE). “The MISSION Phase 2 topline results… [Read More]